These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 21519005)

  • 41. Acetylcholine receptor antibodies in myasthenia gravis.
    Kornfeld P; Nall J; Smith H; Mittag TW; Bender AN; Ambinder EP; Horowitz SH; Papatestas AE; Gross H; Genkins G
    Muscle Nerve; 1981; 4(5):413-9. PubMed ID: 6974823
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Coexistence of myasthenia gravis and serological markers of neurological autoimmunity in neuromyelitis optica.
    McKeon A; Lennon VA; Jacob A; Matiello M; Lucchinetti CF; Kale N; Chan KH; Weinshenker BG; Apiwattinakul M; Wingerchuk DM; Pittock SJ
    Muscle Nerve; 2009 Jan; 39(1):87-90. PubMed ID: 19086079
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Myasthenia gravis: a model disorder of acetylcholine receptors.
    Drachman DB
    Res Publ Assoc Res Nerv Ment Dis; 1987; 65():65-82. PubMed ID: 3330842
    [No Abstract]   [Full Text] [Related]  

  • 44. Epidemiology of myasthenia gravis in Northern Portugal: Frequency estimates and clinical epidemiological distribution of cases.
    Santos E; Coutinho E; Moreira I; Silva AM; Lopes D; Costa H; Silveira F; Nadais G; Morais H; Martins J; Branco MC; Veiga A; Silva RS; Ferreira A; Sousa F; Freijo M; Matos I; André R; Negrão L; Fraga C; Santos M; Sampaio M; Lopes C; Leite MI; Gonçalves G
    Muscle Nerve; 2016 Sep; 54(3):413-21. PubMed ID: 26851892
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Myasthenia gravis exacerbation associated with pembrolizumab.
    Zhu J; Li Y
    Muscle Nerve; 2016 Sep; 54(3):506-7. PubMed ID: 26802533
    [No Abstract]   [Full Text] [Related]  

  • 46. Myasthenia gravis: a higher than expected incidence in the elderly.
    Aragonès JM; Bolíbar I; Bonfill X; Bufill E; Mummany A; Alonso F; Illa I
    Neurology; 2003 Mar; 60(6):1024-6. PubMed ID: 12654975
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Age factors in myasthenia gravis: comparison of cases with the first onset prior to age 50 and over 50].
    Morimatsu M; Komatsu M; Hirai S; Okamoto K; Eto F
    Nihon Ronen Igakkai Zasshi; 1983 Sep; 20(5):376-84. PubMed ID: 6672355
    [No Abstract]   [Full Text] [Related]  

  • 48. Cut off selection in anti-acetylcholine receptor antibody determination.
    Martínez-Castrillo JC; Orensanz LM; Jiménez-Escrig A; Somoza E
    J Neurol Neurosurg Psychiatry; 1994 Aug; 57(8):1018. PubMed ID: 8057104
    [No Abstract]   [Full Text] [Related]  

  • 49. SARS-CoV-2 and myasthenia.
    Finsterer J; Scorza FA; Scorza CA; Fiorini AC
    J Med Virol; 2021 Jul; 93(7):4133-4135. PubMed ID: 32910499
    [No Abstract]   [Full Text] [Related]  

  • 50. Ocular myasthenia. Multiple recurrences and spontaneous remissions.
    Hochman MS
    JAMA; 1982 Jan; 247(1):62. PubMed ID: 7053445
    [No Abstract]   [Full Text] [Related]  

  • 51. Co-occurrence of multiple sclerosis and myasthenia gravis in British Columbia.
    Isbister CM; Mackenzie PJ; Anderson D; Wade NK; Oger J
    Mult Scler; 2003 Dec; 9(6):550-3. PubMed ID: 14664466
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Epidemiology of myasthenia gravis in the Republic of Belarus].
    Likhachev SA; Kulikova SL; Astapenko AV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(1):54-7. PubMed ID: 24637818
    [No Abstract]   [Full Text] [Related]  

  • 53. The epidemiology of myasthenia gravis in central and western Virginia.
    Phillips LH; Torner JC; Anderson MS; Cox GM
    Neurology; 1992 Oct; 42(10):1888-93. PubMed ID: 1407568
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Determinants of cognitive impairment in elderly myasthenia gravis patients.
    Marra C; Marsili F; Quaranta D; Evoli A
    Muscle Nerve; 2009 Dec; 40(6):952-9. PubMed ID: 19768771
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The gender gap in autoimmune disease.
    Poulas K; Tzartos SJ
    Lancet; 2001 Jan; 357(9251):234. PubMed ID: 11213129
    [No Abstract]   [Full Text] [Related]  

  • 56. The incidence of myasthenia gravis: a systematic literature review.
    McGrogan A; Sneddon S; de Vries CS
    Neuroepidemiology; 2010; 34(3):171-83. PubMed ID: 20130418
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Myasthenia gravis: a disease of the very old.
    Aragonès JM; Roura-Poch P; Hernández-Ocampo EM; Alonso F; Pont-Lluelles M; Xandri I; Bolíbar I; Illa I
    J Am Geriatr Soc; 2014 Jan; 62(1):196-7. PubMed ID: 25180387
    [No Abstract]   [Full Text] [Related]  

  • 58. Myasthenia gravis with systemic and neurological polyautoimmunity.
    Duarte S; Santos E; Martins J; Martins Silva A; Lopes C; Gonçalves G; Leite MI
    J Neurol Sci; 2017 Oct; 381():39-40. PubMed ID: 28991712
    [No Abstract]   [Full Text] [Related]  

  • 59. Incidence of myasthenia gravis in the Emilia-Romagna region: a prospective multicenter study. Emilia-Romagna Study Group on Clinical and Epidemiological Problems in Neurology.
    Emilia-Romagna Study Group on Clinical and Epidemiological Problems in Neurology
    Neurology; 1998 Jul; 51(1):255-8. PubMed ID: 9674813
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Epidemiologic evidence for a changing natural history of myasthenia gravis.
    Phillips LH; Torner JC
    Neurology; 1996 Nov; 47(5):1233-8. PubMed ID: 8909435
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.